It can be seen from the current ongoing phase III clinical trials in cervical cancer that PD-1 inhibitors include Pembrolizumab, Camrelizumab, Cemiplimab, Prolgolimab (BCD-100), and QL-1604, while PD-L1 inhibitors include Durvalumab and Atezoliznmab. Here, CD274 is linked to cervical carcinoma.